Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the pancreas~  * Metastatic disease~ * Not amenable to treatment~ * No localized or locally advanced disease~* Measurable disease (metastatic or primary tumor) defined as ≥ 2 cm by CT scan or ≥ 1 cm by spiral CT scan or MRI~* No progressive thrombo-embolic disease~* No adenocarcinoma of the biliary tract or ampulla of Vater~* No known CNS metastases~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Life expectancy \> 12 weeks~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL~* Alkaline phosphatase \< 5 times normal~* Bilirubin \< 1.5 times normal~* Creatinine \< 1.5 times normal~* Creatinine clearance \< 30 mL/min~* Pain controlled or stabilized via analgesic therapy~* Affiliation with social security system~* Not pregnant or nursing~* No controlled or uncontrolled jaundice~* No contraindication to study drugs~* No cardiovascular accident (myocardial infarction, cerebral vascular accident) within the past 6 months~* No serious cardiac and/or respiratory disease~* No other cancer in the past 5 years except the following cancers, provided they have been completely resected:~  * Skin cancer~ * Localized melanoma~ * Carcinoma in situ of the cervix~* No history of thrombophilia~* No history of heparin-induced thrombocytopenia~* No uncontrolled or persistent hypercalcemia~* No psychological, familial, social, and/or geographical condition that precludes participation in the study~PRIOR CONCURRENT THERAPY:~* No prior hematologic therapy for metastatic disease~* No prior abdominal radiotherapy~* No concurrent corticosteroids as anti-emetic therapy~* No other concurrent anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- chemotherapy (Type: ACTIVE_COMPARATOR): chemotherapy at investigator's discretion
- dalteparin (Type: EXPERIMENTAL): dalteparin: 5000 UI sub-cutaneous injection, from Day 1 to Day 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).